JP2021525746A5 - - Google Patents

Info

Publication number
JP2021525746A5
JP2021525746A5 JP2020566737A JP2020566737A JP2021525746A5 JP 2021525746 A5 JP2021525746 A5 JP 2021525746A5 JP 2020566737 A JP2020566737 A JP 2020566737A JP 2020566737 A JP2020566737 A JP 2020566737A JP 2021525746 A5 JP2021525746 A5 JP 2021525746A5
Authority
JP
Japan
Prior art keywords
composition
subject
food
sepiapterin
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566737A
Other languages
English (en)
Japanese (ja)
Other versions
JP7547215B2 (ja
JP2021525746A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034515 external-priority patent/WO2019232126A1/en
Publication of JP2021525746A publication Critical patent/JP2021525746A/ja
Publication of JP2021525746A5 publication Critical patent/JP2021525746A5/ja
Priority to JP2024146283A priority Critical patent/JP7855033B2/ja
Application granted granted Critical
Publication of JP7547215B2 publication Critical patent/JP7547215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566737A 2018-05-30 2019-05-30 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 Active JP7547215B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024146283A JP7855033B2 (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677926P 2018-05-30 2018-05-30
US62/677,926 2018-05-30
US201862771397P 2018-11-26 2018-11-26
US62/771,397 2018-11-26
US201962822365P 2019-03-22 2019-03-22
US62/822,365 2019-03-22
GC201937662 2019-05-28
GC2019-37662 2019-05-28
PCT/US2019/034515 WO2019232126A1 (en) 2018-05-30 2019-05-30 Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024146283A Division JP7855033B2 (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2021525746A JP2021525746A (ja) 2021-09-27
JP2021525746A5 true JP2021525746A5 (cg-RX-API-DMAC10.html) 2022-06-03
JP7547215B2 JP7547215B2 (ja) 2024-09-09

Family

ID=68699016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566737A Active JP7547215B2 (ja) 2018-05-30 2019-05-30 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
JP2024146283A Active JP7855033B2 (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024146283A Active JP7855033B2 (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Country Status (22)

Country Link
US (2) US12257252B2 (cg-RX-API-DMAC10.html)
EP (2) EP3801534B1 (cg-RX-API-DMAC10.html)
JP (2) JP7547215B2 (cg-RX-API-DMAC10.html)
CN (1) CN112654356A (cg-RX-API-DMAC10.html)
BR (1) BR112020024329A2 (cg-RX-API-DMAC10.html)
CA (1) CA3102105A1 (cg-RX-API-DMAC10.html)
DK (1) DK3801534T3 (cg-RX-API-DMAC10.html)
ES (1) ES3068414T3 (cg-RX-API-DMAC10.html)
FI (1) FI3801534T3 (cg-RX-API-DMAC10.html)
FR (1) FR26C1028I1 (cg-RX-API-DMAC10.html)
HR (1) HRP20260360T1 (cg-RX-API-DMAC10.html)
LT (2) LT3801534T (cg-RX-API-DMAC10.html)
MD (1) MD3801534T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020012980A (cg-RX-API-DMAC10.html)
NL (1) NL301382I2 (cg-RX-API-DMAC10.html)
NO (1) NO2026028I1 (cg-RX-API-DMAC10.html)
PL (1) PL3801534T3 (cg-RX-API-DMAC10.html)
PT (1) PT3801534T (cg-RX-API-DMAC10.html)
RS (1) RS68045B1 (cg-RX-API-DMAC10.html)
SI (1) SI3801534T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600220T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019232126A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) * 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
US12298026B1 (en) 2021-04-12 2025-05-13 W. L. Gore & Associates, Inc. Latent energy transfer laminate for plate pack core

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) * 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) * 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
EP3213062B1 (en) 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) * 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Similar Documents

Publication Publication Date Title
EP3236943B1 (en) Compositions for ileo-jejunal drug delivery
JP2021525729A5 (cg-RX-API-DMAC10.html)
JP2024069192A5 (cg-RX-API-DMAC10.html)
CN103191075B (zh) 他达拉非的口服药物制剂
AU2009273361B2 (en) Pharmaceutical formulation for treating the upper digestive tract
EP3003384B1 (en) Oral solution comprising atomoxetine hydrochloride
WO2022104091A1 (en) Rapidly infusing compositions for oral mucosal delivery and methods
WO2013081565A1 (en) Pharmaceutical compositions comprising roflumilast and terbutaline
WO2020148271A1 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
EA034992B1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
JP5235416B2 (ja) 固体投与形中のテトラサイクリン金属錯体
EP2374479A2 (en) Controlled-release composition for producing sustained-release preparation containing udenafil
CN114585362B (zh) 治疗制剂及其用途
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
EP3236949B1 (en) Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof
JP2025506890A (ja) 治療用の化合物、製剤、およびそれらの使用
JP2007530692A (ja) 6−メルカプトプリンの改良された製剤
EP3131631B1 (en) Sitagliptin tannate complex
EP2709596A1 (en) Effervescent formulations comprising dexketoprofen
JP7738832B2 (ja) 低亜鉛血症治療剤
WO2025023901A1 (en) The pharmaceutical combination comprising phosphodiesterase type-5 inhibitor and l-arginine
WO2023247949A1 (en) An orodispersible pharmaceutical composition of baclofen and its process of preparation
CN116847842A (zh) Irak4降解剂和其用途
JP5977672B2 (ja) イブプロフェンリシナートの経口投与用の懸濁液
WO2021202990A2 (en) Methods for the treatment of betacoronavirus infections